Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Onc boards > Targeted therapy- other > Flashcards

Targeted therapy- other Flashcards

1
Q

Erdafitinib

A

FGFR2/3 mutation/fusion

Metastatic urothelial cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pemigatinib

A

FGF2 fusion

Previously treated metastatic cholangio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Selpercatinib

A

RET fusion/mutation
Thyroid
NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pralsetinib

A

RET fusion

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Alpelisib

A

PIK3CA mutation

Post-menopausal women/men with HR+, HER2- metastatic breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Avapritinib

A

PDGFRA exon 18 mutation

Unresectable/metastatic GIST

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Tazemetostat

A

EZH2 mutation
SMARCA mutation
Metastatic epithelioid sarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Olaparib

A 
BRCA1/2 mutation
2nd line metastatic breast
4th line metastatic ovarian
Recurrent/advanced ovarian maintenance
Prostate
Pancreatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Rucaparib

A

BRCA1/2 mutation
3rd line metastatic ovarian
Recurrent ovarian maintenance
Prostate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Talazoparib

A

BRCA1/2

Metastatic breast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dabrafenib

A

BRAF V600E/K
Melanoma
NSCLC
Anaplastic thyroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vemurafenib

A

BRAF V600E/K

Melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Encorafenib

A

BRAF V600E/K
Melanoma
Colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Trametinib

A 
MEK inhibitor
Only approved in combo with dabrafenib
Melanoma
NSCLC
Anaplastic thyroid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cobimetinib

A

MEK inhibitor
Only approved in combo with vemurafenib
Melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Binimetinib

A

MEK inhibitor
Only approved in combo with encorafenib
Melanoma

17
Q

Obinutuzumab

18
Q

Ofatumumab

19
Q

Brentuximab

Onc boards (24 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions